Bill, age 59. Wants to fight his cancer, but also wants to know what side effects are related to his treatment.
"I want to fight my cancer, but I also want to know what side effects are related to my treatment."
- Attorney who travels for business
- Focuses on his professional appearance
- Stays active and enjoys the outdoors
Bill wants a proven treatment with a well-established safety profile.
For Bill, what is your choice for an effective treatment with a well-established safety profile?
Fred, age 64. Is prepared to fight, but curious about the tolerability of different treatment options.
"I am prepared to fight, but what about the tolerability of my treatment options?"
- Runs his own accounting firm and is an avid golfer
- Married father of 2 grown children
- Maintains a busy work and social schedule
Fred wants a treatment with both proven efficacy and a well-established safety profile.
For Fred, what is your choice for an effective treatment with a well-established safety profile?
Important Safety Information (cont'd)
Warnings and Precautions (cont'd)
Bone Marrow Suppression (cont'd): For 7 of 13 patients treated with Xofigo bone marrow failure was ongoing at the time of death. Among the 13 patients who experienced bone marrow failure, 54% required blood transfusions. Four percent (4%) of patients in the Xofigo arm and 2% in the placebo arm permanently discontinued therapy due to bone marrow suppression.
Please see additional Important Safety Information below.
James, age 78. Wants to continue with treatment and learn about what side effects he can expect.
"I want to continue with treatment, but what side effects can I expect from my options?"
- Retired businessman who enjoys playing chess and board games
- Widowed 5 years ago, but has the strong support of his 3 sons and grandchildren
- Enjoys monthly visits with his grandchildren
Effective cancer treatment with a well-established safety profile is important to James.
For James, what is your choice for an effective treatment with a well-established safety profile?
TIMING OF XOFIGO TREATMENT IS CRITICAL
Start Xofigo or refer to a treatment site when your patient has the following
Rising PSA on androgen deprivation therapy with testosterone ≤50 ng/dL, indicating castration-resistant prostate cancer1a
Symptoms attributable to bone metastases2
≥2 bone metastases2
No known visceral metastases2
Also consider for patients who
- Have lymphadenopathy up to 3 cm in the short axis2
- Are referred for external-beam radiation therapy (EBRT) as part of best standard of care (BSOC)b
aSerum PSA progression defined as 2 consecutive increases in PSA over a previous reference.
bIn the ALSYMPCA clinical trial, Xofigo was given with BSOC, which included antiandrogens, ketoconazole, local EBRT, estrogens, estramustine, or treatment with glucocorticoids.3
- Scher HI, Morris MJ, Stadler WM, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3. J Clin Oncol. 2016;34(12):1402-1418. Return to content
- Xofigo® (radium Ra 223 dichloride) injection [prescribing information].Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc.; December 2019. Return to content
- Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3):213-223. Return to content